tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Intertrigo D007402 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morello RJ et al. Remote ischemic preconditioning and tacrolimus in the fetal small bowel transplant in mice. 2016 Acta Cir Bras pmid:27828601
Vohra S et al. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. 2016 Int. J. Dermatol. pmid:26147635
Anderson K et al. A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor. 2016 J Dermatolog Treat pmid:26138407
Merino D et al. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment. 2016 Immunology pmid:26931075
Lee SG et al. Enhanced topical delivery of tacrolimus by a carbomer hydrogel formulation with transcutol P. 2016 Drug Dev Ind Pharm pmid:26925849
Doke T et al. Post-Transplant Membranous Nephropathy Associated with Chronic Active Antibody-Mediated Rejection and Hepatitis C Infection after Deceased Donor Renal Transplantation. 2016 Intern. Med. pmid:26875963
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Koura-Nishiura A et al. Clearance of atypical facial necrobiosis lipoidica with tacrolimus ointment. 2016 J Eur Acad Dermatol Venereol pmid:25353715
Lee SH et al. Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial
. 2016 Clin. Nephrol. pmid:27781419
Nascimento J and Machado S Pediatric-onset necrobiosis lipoidica. 2016 Pediatr Int pmid:26865027
Ueno KI et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. 2016 Int J Rheum Dis pmid:27457756
Barreto P et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. 2016 Transplant. Proc. pmid:27742278
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Robinson CL et al. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. 2016 Transpl Infect Dis pmid:26781986
Rodríguez-Lago I et al. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. 2016 Rev Esp Enferm Dig pmid:27604685
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Rostaing L et al. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. 2016 Am. J. Kidney Dis. pmid:26717860
Spain L et al. Management of toxicities of immune checkpoint inhibitors. 2016 Cancer Treat. Rev. pmid:26874776
Ocampo-Garza J et al. Acquired Hyperpigmentation and Cicatricial Alopecia. 2016 Am. J. Med. Sci. pmid:27524226
Solomon A Allergic manifestations of contact lens wearing. 2016 Curr Opin Allergy Clin Immunol pmid:27518840
Jung HJ et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. 2016 Int. J. Biol. Macromol. pmid:26642839
Cassuto E et al. Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study. 2016 Transplantation pmid:27653227
Saliba F et al. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. 2016 Transplantation pmid:27454919
Butts AR et al. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation. 2016 J Oncol Pharm Pract pmid:25802301
Belliere J et al. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia. 2016 Transpl. Int. pmid:26575959
Zhao CY et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. 2016 Br J Clin Pharmacol pmid:26574188
Zhang X et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. 2016 Int Urol Nephrol pmid:26781720
Grönhagen CM and Tey HL Meralgia paresthetica successfully treated with topical 0.1% tacrolimus: a case report. 2016 Int. J. Dermatol. pmid:26518996
Korobko IV and Lomonosov KM A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. 2016 Dermatol Ther pmid:27329330
Vadcharavivad S et al. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients. 2016 Ther Drug Monit pmid:27328329
Wu H et al. Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice. 2016 PLoS ONE pmid:27606422
Luo X et al. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. 2016 Acta Pharmacol. Sin. pmid:26924289
McShane AJ et al. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. 2016 Clin. Chim. Acta pmid:26721314
Kostereva NV et al. IGF-1 and Chondroitinase ABC Augment Nerve Regeneration after Vascularized Composite Limb Allotransplantation. 2016 PLoS ONE pmid:27272754
Raja R et al. A prospective study of collapsing focal segmental glomerulosclerosis. 2016 Ren Fail pmid:27266801
De Meyer M et al. Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. 2016 Pharmacogenomics pmid:27266721
Bagherani N Comparison of pimecrolimus with clobetasol propionate in the treatment of localized vitiligo. 2016 Dermatol Ther pmid:26445411
Gaynor JJ et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. 2016 Transpl. Int. pmid:26442829
Ahmad M et al. Effectiveness of minocycline and FK506 alone and in combination on enhanced behavioral and biochemical recovery from spinal cord injury in rats. 2016 Pharmacol. Biochem. Behav. pmid:27106204
Ha DH et al. Effects of tacrolimus on morphology, proliferation and differentiation of mesenchymal stem cells derived from gingiva tissue. 2016 Mol Med Rep pmid:27177273
Jin J et al. Klotho Deficiency Aggravates Tacrolimus-Induced Renal Injury via the Phosphatidylinositol 3-Kinase-Akt-Forkhead Box Protein O Pathway. 2016 Am. J. Nephrol. pmid:27174564
Kim JM et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study. 2016 Liver Transpl. pmid:26360125
Bican Demir A et al. Two Cases With Developing Neurologic Complications After Liver Transplant. 2016 Exp Clin Transplant pmid:26643318
Bruns K et al. Quantitative determination of four immunosuppressants by high resolution mass spectrometry (HRMS). 2016 Clin. Chem. Lab. Med. pmid:26641969
Zamorano-Leon JJ et al. New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. 2016 Transpl. Immunol. pmid:27102446
Park OJ et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. 2016 Clin. Exp. Dermatol. pmid:26299799
Watanabe H et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. 2016 Lupus pmid:26296361
Ko DH et al. Performance Evaluation of a Restored Dimension TACR Assay: An Automated Platform for Measuring the Whole Blood Tacrolimus Concentration. 2016 Clin. Lab. pmid:27012028
Tang JT et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. 2016 Expert Opin Drug Metab Toxicol pmid:27010623
Wakamatsu A et al. Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. 2016 Physiol Rep pmid:27009276